Categoria: Abstract

Tabernero J,  Van Cutsem E, Yoshino T, et al. Background: BRAF mutations occur in 8% to 12% of patients with mCRC and are associated with clinically poor prognosis. E+C was approved by the FDA and EMA for patients with BRAF V600E-mutant mCRC who have received prior systemic therapy based on the results of the BEACON...

T. Kato T,  Kotani D, Takashima A, et al. Background: The triplet combination of encorafenib, cetuximab, plus binimetinib (BEACON triplet regimen) showed survival benefit and a higher response over standard chemotherapy in pretreated patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the BEACON CRC study. The BEACON triplet regimen as well as encorafenib plus...

Morris V, Guthrie K, Kopetz S, et al. Background: Patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer (mCRC) experience poor survival outcomes relative to their MSS, BRAFwild-type CRC counterparts. Treatment with the BRAF inhibitor encorafenib (E) and anti-EGFR antibody cetuximab (C) is an approved treatment combination based on the phase III BEACON trial, with...

Liposits G, Jesper R, Winther S, et al. Background: Colorectal cancer has the highest incidence and mortality rate in individuals ≥70 years. Survival has substantially improved in young and fit patients with metastatic colorectal cancer (mCRC) eligible for intensive treatment (doublet/triplet chemotherapy ± targeted agents) through the past decades, however, this benefit is less clear...

Germani MM, et al. Background: Encorafenib plus cetuximab is a standard option in the treatment of BRAF V600E mut mCRC pts pre-treated with at least one systemic therapy. RNF43 is a negative regulator of WNT pathway. A recent study showed that RNF43 mutation is associated with better outcome among pMMR/MSS BRAF V600E mut mCRC patients treated with TT but not in an independent...

Samalin E, Lorenzon L,  Sarrauste de Menthière C, et al. Background: Approximately 500,000 people are diagnosed with colorectal cancer (CRC) every year in Europe [1]. Approximately 15 to 30% of these patients are initially diagnosed at a metastatic stage (mCRC), and 20% to 50% of patients with initially localized disease will relapse and present metastasis...

Prager G, Santini D, Modest D, et al. Background: Collating real-world data is an important way of understanding evolving treatment patterns in oncology. The aim of the SCOPE gastrointestinal (GI) cancers program was to gather insights on real-world practice patterns in the management of metastatic (m) gastric cancer, colorectal cancer (CRC), and pancreatic cancer. Herein,...

Wasan H,  Lonardi S, Desai J, et al. Background: The BRAF inhibitor encorafenib, in combination with cetuximab (EC), has recently been approved for patients with BRAFV600E-mutated metastatic colorectal cancer (BRAFV600E-mCRC) after prior systemic therapy. As the combination is the first BRAF inhibitor-based regimen approved for BRAFV600E-mCRC the goal of this analysis was to explore novel...

Douik H, G. Sahraoui G, Doghri R, et al. Background: Target therapy in metastatic colorectal cancer needs the determination of KRAS, NRAS, and BRAF mutation status to identify patients resistant to anti-EGFR treatment. RASgenes (KRAS+NRAS) are mutated in 40-50% of metastatic colorectal cancer and BRAF in 5-10%; the presence of a double mutation in RAS...

Hassan MA, Gyi M, Sethupathi M Background: Somatic mutation testing has revolutionized management of metastatic colon cancer. BRAF mutant colon cancer is known to be associated with poor prognosis, and usually presents with distant lymph node involvement and peritoneal metastases. Atypical metastatic pattern may be a feature and can represent a difficult challenge for treating...